Phase 2 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People whose cancer has at least one measurable area of disease, as seen on scans (using a standard measurement method called RECIST v1.1)
- People who have already tried at least one prior cancer treatment, and either have no remaining standard treatment options that are expected to help, or are unable to tolerate or have chosen not to continue standard treatments
- People who are relatively well and able to carry out daily activities (measured by a standard scale called ECOG, with a score of 0 or 1)
- People with a life expectancy of at least 3 months
- People with adequate bone marrow function (confirm with trial site for specific values)
- People with adequate liver function (confirm with trial site for specific values)
- People with adequate kidney function, as measured by a specific calculation showing the kidneys are filtering at a sufficient rate
- People who have a confirmed diagnosis of one of the following cancer types: head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal cancer, gastric (stomach) cancer, biliary tract cancer, pancreatic ductal adenocarcinoma, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, urothelial carcinoma, neuroendocrine tumor or carcinoma, soft tissue sarcoma, or NUT carcinoma
Who may not be able to join:
- People whose cancer has spread to the brain or the lining around the brain and spinal cord, and where that spread is currently active
- People who still have unresolved side effects from previous cancer treatments that are rated at a moderate level or higher (Grade 2 or above), except for hair loss
- People who have received systemic (whole-body) cancer treatment within approximately the last 4 weeks, or radiation therapy within the last 2 weeks, before starting the trial
- People with a personal history of a heart condition called congenital long QT syndrome, or certain serious abnormal heart rhythms such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes
- People who have recently taken medications known to affect the heart's electrical activity in a specific way (known as QT prolongation risk) within approximately 2 weeks before starting the trial
- People whose heart electrical activity screening result (called QTcF interval) shows a reading above 470 milliseconds
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Head of Medical Science, Tanabe Pharma America, Inc.
Phone: Please E-mail
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Adverse Event, Dose limiting toxicities (DLTs); Number of Patients with Adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.